 |
BioWorld-International-2005-05-25
Merck Licenses BioXell's TREM Receptor Programs For $150M
Merck Licenses BioXell's TREM Receptor Programs For $150M
BioXell SpA could earn up to $150 million in milestone payments from Merck & Co. Inc., which has gained exclusive commercialization rights to BioXell's preclinical TREM (Triggering Receptors Expressed on Myeloid Cells) programs. (BioWorld International)